Microbot Medical (NASDAQ:MBOT) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Posted by Linda Flegge on Apr 22nd, 2025

Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.44 and traded as high as $2.53. Microbot Medical shares last traded at $2.23, with a volume of 2,045,535 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Microbot Medical in a report on Thursday, April 10th.

Read Our Latest Stock Report on MBOT

Microbot Medical Price Performance

The firm has a market capitalization of $77.48 million, a price-to-earnings ratio of -2.79 and a beta of 1.40. The firm’s fifty day moving average is $1.70 and its 200 day moving average is $1.44.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last posted its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Equities research analysts forecast that Microbot Medical Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of Microbot Medical

A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC bought a new position in Microbot Medical Inc. (NASDAQ:MBOT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

(Get Free Report)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.